139-OR: ADA Presidents’ Select Abstract: Potential Gains in Life Expectancy (LE) Associated with Achieving Treatment Goals in People with Type 2 Diabetes (T2D) in the U.S.

Abstract

Achieving treatment goals could prolong life in people with T2D, but this benefit has not been thoroughly examined. We quantified potential gains in LE from achieving different levels of A1c, systolic blood pressure (SBP), low-density lipoproteins (LDL), and body mass index (BMI). We previously developed and extensively validated the BRAVO diabetes miscrosimulation model. In current tudy, we calibrated the BRAVO diabetes model to a US representative cohort, using the 2011-2012 National Health and Nutrition Examination Survey and its linked mortality records from the National Death Index. We then used the BRAVO model to project LE by level of A1c, SBP, LDL, and BMI. We found that reducing BMI was associated with the largest gain in LE, followed by lowering SBP, and then LDL (Figure). A reduction in A1c from 4th (mean: 9.1%) to 3rd (mean: 7.2%) quartile was associated with a gain of about 2 years, but further A1c reduction was associated with little gains in LE. Our findings can be used to assist communications between clinicians and patients to motivate patients in achieving the recommended treatment goals, and to measure potential health benefits for interventions/programs to improve diabetes care in the US. Disclosure H. Kianmehr: None. P. Zhang: None. M. E. Pavkov: None. K. M. Bullard: None. V. Fonseca: Consultant; Self; Abbott Diabetes, Asahi Kasei Corporation, Bayer Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Intarcia Therapeutics, Inc., Novo Nordisk, Pfizer Inc., Sanofi-Aventis, Stock/Shareholder; Self; Amgen Inc., Bravo4health, Mellitus Health. L. Shi: Research Support; Self; AstraZeneca, Sanofi. H. Shao: Research Support; Self; Sanofi.